GlassScriptPhysician profile
Caitlin Lopez
NPI 1821658378
$11,756.72
in general payments reported to CMS, 2019-2025
47 companies · $3,045 in 2025
The $3,045 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,741 · 2022: $2,494 · 2023: $1,893 · 2024: $2,583 · 2025: $3,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,521.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,581.61 | 2021-2025 | |
| Biogen, INC. | $1,548.99 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $1,284.60 | 2021-2025 | |
| Ucb, INC. | $644.74 | 2023-2025 | Briviact, Fintepla, Rystiggo |
| Argenx US, INC. | $534.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $523.90 | 2021-2025 | Mavenclad |
| Lilly USA, LLC | $485.97 | 2021-2025 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $411.54 | 2021-2025 | |
| Celgene Corporation | $409.96 | 2021-2024 | Zeposia |
| Sk Life Science, INC. | $401.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $346.60 | 2021-2025 | Wainua, Andexxa |
| Amgen INC. | $302.79 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $283.48 | 2021-2024 | Ztlido |
| Alnylam Pharmaceuticals INC. | $253.88 | 2021-2025 | Amvuttra |
| Neurocrine Biosciences, INC. | $238.41 | 2024-2025 | Ingrezza |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $225.27 | 2025 | Ponvory |
| Neurelis, INC. | $218.83 | 2023-2025 | Valtoco |
| Genzyme Corporation | $196.20 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $173.30 | 2021-2024 | Zeposia |
| Eisai INC. | $144.63 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $138.86 | 2021-2025 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $134.77 | 2023-2025 | Ultomiris, Soliris |
| Kyowa Kirin, INC. | $133.47 | 2021-2022 | |
| Boston Scientific Corporation | $112.38 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $101.29 | 2021-2022 | |
| Genentech USA, INC. | $98.80 | 2024-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biohaven Pharmaceuticals, INC. | $80.83 | 2021 | |
| Ani Pharmaceuticals, INC. | $77.24 | 2025 | Purified Cortrophin Gel |
| Nevro Corp. | $77.05 | 2021-2022 | |
| Lundbeck LLC | $66.34 | 2024-2025 | Vyepti |
| Upsher-Smith Laboratories LLC | $60.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.84 | 2022 | |
| Stimwave Technologies Incorporated | $47.15 | 2022 | |
| Saluda Medical Americas, INC. | $41.74 | 2024 | Evoke |
| Si-Bone, INC. | $40.20 | 2025 | |
| Medtronic, INC. | $37.16 | 2022-2024 | Intellis Adaptivestim |
| Globus Medical, INC. | $34.83 | 2025 | Senza |
| Horizon Therapeutics Plc | $33.59 | 2023 | Uplizna |
| Mdd US Operations, LLC | $22.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.04 | 2025 | Hyqvia |
| Grt US Holding, INC. | $22.04 | 2021-2022 | |
| Csl Behring | $21.72 | 2025 | Hizentra |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.20 | 2023 | Rytary |
| Averitas Pharma INC. | $19.13 | 2025 | Qutenza |
| Axsome Therapeutics, INC. | $16.86 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.71 | 2024 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.